JP2021512087A5 - - Google Patents

Info

Publication number
JP2021512087A5
JP2021512087A5 JP2020541535A JP2020541535A JP2021512087A5 JP 2021512087 A5 JP2021512087 A5 JP 2021512087A5 JP 2020541535 A JP2020541535 A JP 2020541535A JP 2020541535 A JP2020541535 A JP 2020541535A JP 2021512087 A5 JP2021512087 A5 JP 2021512087A5
Authority
JP
Japan
Prior art keywords
egfr
alkyl
independently
halogen
monosubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512087A (ja
JP7427597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/073355 external-priority patent/WO2019149164A1/en
Publication of JP2021512087A publication Critical patent/JP2021512087A/ja
Publication of JP2021512087A5 publication Critical patent/JP2021512087A5/ja
Priority to JP2023180451A priority Critical patent/JP7738619B2/ja
Application granted granted Critical
Publication of JP7427597B2 publication Critical patent/JP7427597B2/ja
Priority to JP2025145276A priority patent/JP2025179139A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541535A 2018-01-31 2019-01-28 Erbb/btk阻害剤 Active JP7427597B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023180451A JP7738619B2 (ja) 2018-01-31 2023-10-19 Erbb/btk阻害剤
JP2025145276A JP2025179139A (ja) 2018-01-31 2025-09-02 Erbb/btk阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/074791 2018-01-31
CN2018074791 2018-01-31
CNPCT/CN2018/118569 2018-11-30
CN2018118569 2018-11-30
PCT/CN2019/073355 WO2019149164A1 (en) 2018-01-31 2019-01-28 Erbb/btk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023180451A Division JP7738619B2 (ja) 2018-01-31 2023-10-19 Erbb/btk阻害剤

Publications (3)

Publication Number Publication Date
JP2021512087A JP2021512087A (ja) 2021-05-13
JP2021512087A5 true JP2021512087A5 (cg-RX-API-DMAC7.html) 2022-02-02
JP7427597B2 JP7427597B2 (ja) 2024-02-05

Family

ID=67478612

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541535A Active JP7427597B2 (ja) 2018-01-31 2019-01-28 Erbb/btk阻害剤
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Erbb/btk阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Erbb/btk阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023180451A Active JP7738619B2 (ja) 2018-01-31 2023-10-19 Erbb/btk阻害剤
JP2025145276A Pending JP2025179139A (ja) 2018-01-31 2025-09-02 Erbb/btk阻害剤

Country Status (14)

Country Link
US (2) US11007198B2 (cg-RX-API-DMAC7.html)
EP (2) EP4356975A3 (cg-RX-API-DMAC7.html)
JP (3) JP7427597B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250046340A (cg-RX-API-DMAC7.html)
CN (4) CN111909131B (cg-RX-API-DMAC7.html)
AU (2) AU2019215538B2 (cg-RX-API-DMAC7.html)
CA (1) CA3086616A1 (cg-RX-API-DMAC7.html)
DK (1) DK3746424T3 (cg-RX-API-DMAC7.html)
ES (1) ES2977484T3 (cg-RX-API-DMAC7.html)
MX (2) MX2020007947A (cg-RX-API-DMAC7.html)
PT (1) PT3746424T (cg-RX-API-DMAC7.html)
RU (1) RU2764069C1 (cg-RX-API-DMAC7.html)
TW (1) TWI798334B (cg-RX-API-DMAC7.html)
WO (1) WO2019149164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲(江蘇)醫藥股份有限公司 Erbb/btk抑制劑
US11896597B2 (en) * 2018-01-31 2024-02-13 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
WO2021104305A1 (zh) * 2019-11-26 2021-06-03 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
CN111057021B (zh) * 2019-12-11 2023-05-23 中国药科大学 均三嗪类化合物及其制备方法和用途
AU2021205834A1 (en) * 2020-01-07 2022-08-25 Dana-Farber Cancer Institute, Inc. Cyano-pyrimidine inhibitors of EGFR/HER2
CN111470998B (zh) * 2020-06-28 2020-09-25 上海皓元生物医药科技有限公司 用于合成喜树碱衍生物的中间体及其制备方法和用途
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
CN112679446A (zh) * 2020-10-26 2021-04-20 都创(上海)医药科技有限公司 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法
CN116670127A (zh) * 2021-03-30 2023-08-29 贝达药业股份有限公司 Egfr抑制剂及其组合物和用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
BR112023025660A2 (pt) * 2021-07-02 2024-02-27 Aldeyra Therapeutics Inc Compostos de captação de aldeído heterocíclicos e usos dos mesmos
AU2022324410A1 (en) * 2021-08-02 2024-01-18 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor
CN115181093B (zh) * 2022-08-01 2023-04-25 重庆医科大学 Sunvozertinib中间体的制备方法
EP4731307A1 (en) 2023-06-23 2026-04-29 Assia Chemical Industries Ltd. Solid state forms of sunvozertinib
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100799534B1 (ko) * 2004-02-27 2008-01-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(1)
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
HUE033177T2 (en) * 2012-01-17 2017-11-28 Astellas Pharma Inc Pyrazine carboxamide compound
JP6317320B2 (ja) * 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
JP6469567B2 (ja) * 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
JP6510510B2 (ja) * 2013-07-11 2019-05-08 ベータ ファーマシューティカルズ カンパニー リミテッド プロテインチロシンキナーゼモジュレーター及び使用方法
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CN105384694B (zh) * 2014-08-22 2020-09-04 四川海思科制药有限公司 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
CN106883213B (zh) * 2015-12-15 2021-04-20 合肥中科普瑞昇生物医药科技有限公司 一种egfr和alk激酶的双重抑制剂
CN106905245B (zh) * 2015-12-23 2021-06-25 正大天晴药业集团股份有限公司 2,4-二取代的嘧啶类化合物
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技(上海)有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲(江蘇)醫藥股份有限公司 Erbb/btk抑制劑
KR102782739B1 (ko) * 2018-03-13 2025-03-20 보로노이 주식회사 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
CN109789146B (zh) 趋化因子受体调节剂及其用途
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2019031560A5 (cg-RX-API-DMAC7.html)
EP4699660A3 (en) Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
JP2018517686A5 (cg-RX-API-DMAC7.html)
JP2019500352A5 (cg-RX-API-DMAC7.html)
JP2021523159A5 (cg-RX-API-DMAC7.html)
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
JP2012513416A5 (cg-RX-API-DMAC7.html)
JP2016513661A5 (cg-RX-API-DMAC7.html)
JP2013010792A5 (cg-RX-API-DMAC7.html)
JP2014501766A5 (cg-RX-API-DMAC7.html)
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2018530549A5 (cg-RX-API-DMAC7.html)
JP2008509949A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
CN111918652A (zh) 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂
JP2018513832A5 (cg-RX-API-DMAC7.html)
RU2016134751A (ru) Соединения
JP2015535831A5 (cg-RX-API-DMAC7.html)
JP2020128426A5 (cg-RX-API-DMAC7.html)
JP2015502367A5 (cg-RX-API-DMAC7.html)